Purpose Sotatercept, an activin signalling inhibitor approved in March 2024 for pulmonary arterial hypertension (PAH), ...
Overview: In 2025, data analytics tools blend AI, cloud, and automation for real-time insights and smarter decisions.Tableau, ...
BACKGROUND: Alternative splicing plays crucial roles in normal heart development and cardiac disease by influencing protein-coding sequences, functional domains, and molecular networks. However, a ...
Background Hospitalisation with acute heart failure (AHF) carries a high risk of death, and those surviving to discharge ...
Background: Determining optimal timing for intensifying the frequency of physician encounters for type 2 diabetes mellitus (T2DM) requires trade-offs between timely care and clinician burden. We aimed ...
The University of Ottawa Heart Institute has launched an ambitious plan to screen one million Canadians for heart disease risks. On Tuesday, Ottawa Mayor Mark Sutcliffe became Patient No. 1.
Improving the analysis of cardiovascular imaging for better patient care. Circle Cardiovascular Imaging (Circle) is a ...
UK: Acute kidney injury (AKI) during pregnancy dramatically amplifies a woman’s risk of serious heart and kidney ...
Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a new type of contactless body data ...
On 15 September 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called REGN5381 (called ...
Clinical Trials Arena on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision. Amgen is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback